All In Biotech

Drug Trial Radar · NCT06850480

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

A Multicenter, Randomized, Double-blind, Double-simulated, Positive Parallel-control Phase III Clinical Trails of JP-1366(Zastaprazan Citrate) Tablets and Nexium® on Reflux Esophagitis

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

356

Planned (sponsor's estimate)

Start

Dec 5, 2024

Primary completion

Apr 15, 2025

Study completion Apr 30, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.

Conditions

  • Reflux Esophagitis (RE)

Interventions

  • JP-1366 simulation tabletsDrug

    qd, last for 4-8 weeks

  • Esomeprazole Magnesium (Nexium) simulation tabletsDrug

    qd, last for 4-8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with esophageal mucosal healing confirmed by upper gastrointestinal endoscopy within 8 weeks of treatmentTime frame: Week 4-8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical Universtiy

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.